News | December 28, 2012

CyberKnife Prostate Outcomes Highlighted During ASTRO Presentations

December 28, 2012 — Accuray Inc. announced clinical findings using noninvasive CyberKnife stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer. Two studies were presented at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston at a prostate-focused press conference, for which the use of CyberKnife SBRT for prostate cancer represented half of the press conference’s focus.

During ASTRO’s scientific sessions, data on CyberKnife prostate SBRT for organ-confined prostate cancer was presented in the form of three podium presentations and seven poster presentations by researchers from leading U.S. academic and community-based cancer treatment centers. In these studies, all patients were treated in five or fewer non-surgical outpatient treatment sessions – far fewer than the 40 or more that patients typically receive with traditional radiotherapy or intensity-modulated radiation therapy (IMRT). Overall, efficacy and toxicity findings compared favorably with longer courses of IMRT, expanding the foundation of evidence supporting the value of CyberKnife prostate SBRT for patients with organ confined prostate cancer.

The following is an overview of the three CyberKnife prostate studies selected for podium presentation by ASTRO’s Review Committee:

Alan J. Katz, M.D., a radiation oncologist with Flushing Radiation Oncology in Flushing, N.Y., presented findings from a multicenter study, organized by researchers at UCLA Medical Center, of outcomes for 1,100 low, intermediate and high-risk prostate cancer treated with CyberKnife SBRT at eight centers within the United States and Italy.

Patients were followed for a median of 36 months, and close to half were followed for at least four years. Actuarial five-year disease-free survival was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients. These findings compare favorably with other surgical and radiation-based treatments.

"These findings are in line with those of the more than 800 patients I’ve treated personally to date, some of whom are up to seven years post-treatment,” said Katz. “I am excited to see the body of long-term data supporting the outcomes of CyberKnife prostate SBRT growing in support of this treatment’s benefits for patients.”

CyberKnife SBRT for patients with intermediate-risk prostate cancer was the focus of a study presented by Robert Meier, M.D., a radiation oncologist with the Swedish Cancer Institute in Seattle, and co-lead by Beth Israel Deaconess Medical Center in Boston. In the multicenter study, 129 patients were treated at 21 centers throughout the United States. At a median follow-up of 36 months, the three-year disease-free survival rate was 99.2 percent, which is higher than those typically seen with external beam radiotherapy. The urinary and rectal side effect profile was as good as or better than other radiotherapy treatments, with comparable sexual function outcomes.

"Our study demonstrates very promising cancer control rates and few side effects, which are in line with the growing body of clinical evidence supporting the value of CyberKnife prostate SBRT,” said Meier. “Through the use of image guidance and robotics, we’re able to continuously track the prostate and concentrate hundreds of radiation beams into the target with sub-millimeter accuracy, which helps us effectively treat the disease while sparing nearby healthy tissue and critical structures.”

Donald Fuller, M.D., a radiation oncologist from Genesis Healthcare in San Diego, presented findings from a multicenter study of 260 patients with low and intermediate-risk prostate cancer treated using CyberKnife SBRT at 17 institutions, using an approach that emulates the dosimetry of high dose rate (HDR) brachytherapy.

Patients were followed for up to 48 months with a median follow-up of 24 months, and found to have disease-free survival of 98.5 percent. Urinary and rectal toxicities reported at a minimum one-year follow-up were in line with outcomes of traditional radiation therapy, and erectile function returned to baseline by three years, with minimal disruption after treatment.

"These findings should encourage men to explore CyberKnife SBRT as a viable alternative to surgery or other radiation treatments, such as brachytherapy and intensity-modulated radiation therapy,” said Fuller. “Findings to date indicate we may be able to minimize the undesirable side effects typically associated with other treatment modalities and help to preserve patients' quality of life during and after prostate cancer treatment.”

Additionally, seven posters highlighting CyberKnife prostate SBRT experience were presented by researchers from the University of California San Francisco, Georgetown University Hospital and Winthrop University Hospital, as well as additional research from Flushing Radiation Oncology and Swedish Cancer Institute in Seattle, further supporting the maturing body of prostate SBRT evidence.

For more information: www.accuray.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
Overlay Init